Bank Pictet & Cie Europe AG Decreases Stock Position in Thermo Fisher Scientific Inc. $TMO

Key Points

• Bank Pictet & Cie Europe AG reduced its stake in Thermo Fisher Scientific Inc. by 49.1% in Q2, now holding 39,704 shares valued at approximately $16.1 million.
• Insider trading indicates a downturn, with executives selling a combined total of 30,066 shares over the last 90 days, which reflects a decrease in their ownership.
• Thermo Fisher Scientific recently reported a net income of $5.36 EPS for the quarter, exceeding analysts' expectations and demonstrating a 2.9% year-over-year revenue increase.

Bank Pictet & Cie Europe AG lowered its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 49.1% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 39,704 shares of the medical research company's stock after selling 38,275 shares during the quarter. Bank Pictet & Cie Europe AG's holdings in Thermo Fisher Scientific were worth $16,098,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of TMO. Brighton Jones LLC increased its stake in shares of Thermo Fisher Scientific by 28.9% during the 4th quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company's stock valued at $2,293,000 after acquiring an additional 988 shares during the last quarter. Revolve Wealth Partners LLC increased its stake in shares of Thermo Fisher Scientific by 4.2% during the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock valued at $255,000 after acquiring an additional 20 shares during the last quarter. Ameriflex Group Inc. acquired a new position in shares of Thermo Fisher Scientific during the 4th quarter valued at about $30,000. Park Square Financial Group LLC acquired a new position in shares of Thermo Fisher Scientific during the 4th quarter valued at about $49,000. Finally, Wealth Enhancement Advisory Services LLC increased its position in Thermo Fisher Scientific by 1.2% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 127,272 shares of the medical research company's stock worth $66,211,000 after purchasing an additional 1,556 shares in the last quarter. Institutional investors and hedge funds own 89.23% of the company's stock.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 400 shares of the firm's stock in a transaction on Friday, July 25th. The stock was sold at an average price of $479.98, for a total value of $191,992.00. Following the sale, the executive vice president directly owned 22,367 shares in the company, valued at approximately $10,735,712.66. This trade represents a 1.76% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CAO Joseph R. Holmes sold 385 shares of the firm's stock in a transaction on Friday, August 29th. The shares were sold at an average price of $492.63, for a total value of $189,662.55. Following the completion of the sale, the chief accounting officer owned 2,319 shares in the company, valued at $1,142,408.97. The trade was a 14.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 30,066 shares of company stock valued at $14,182,963 over the last 90 days. 0.33% of the stock is owned by company insiders.

Thermo Fisher Scientific Stock Down 1.9%

TMO stock opened at $459.34 on Friday. The company has a market capitalization of $173.45 billion, a P/E ratio of 26.57, a PEG ratio of 2.54 and a beta of 0.75. The firm has a 50 day simple moving average of $475.73 and a 200-day simple moving average of $448.37. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65. Thermo Fisher Scientific Inc. has a twelve month low of $385.46 and a twelve month high of $623.77.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, topping analysts' consensus estimates of $5.22 by $0.14. The firm had revenue of $10.86 billion during the quarter, compared to the consensus estimate of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The firm's revenue was up 2.9% on a year-over-year basis. During the same quarter in the previous year, the company posted $5.37 earnings per share. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, equities research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date of this dividend is Monday, September 15th. Thermo Fisher Scientific's payout ratio is currently 9.95%.

Analyst Upgrades and Downgrades

TMO has been the subject of a number of research analyst reports. Barclays raised shares of Thermo Fisher Scientific from an "equal weight" rating to an "overweight" rating and increased their target price for the stock from $490.00 to $550.00 in a research report on Thursday, September 11th. UBS Group increased their target price on shares of Thermo Fisher Scientific from $460.00 to $500.00 and gave the stock a "neutral" rating in a research report on Thursday, July 24th. Evercore ISI dropped their target price on shares of Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating for the company in a research report on Tuesday, July 8th. William Blair initiated coverage on shares of Thermo Fisher Scientific in a research report on Monday, August 18th. They set an "outperform" rating for the company. Finally, Raymond James Financial reissued an "outperform" rating and set a $535.00 target price (up previously from $525.00) on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Sixteen analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $588.35.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.